News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Patrizia Giannatempo: Phase 1/2 Duravelo-1 study
Patrizia Giannatempo/X
May 28, 2025, 03:50

Patrizia Giannatempo: Phase 1/2 Duravelo-1 study

Patrizia Giannatempo, Medical Oncology Consultant at the National Cancer Institute (INT) in Milan, shared a post on X:

“ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2).
Bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). Encouraging tolerability.”

Title: Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

Authors: Patrizia Giannatempo, Matthew Galsky, Ignacio Duran, Valentina Boni, Andrea Necchi, Antoine Italiano, Meredith McKean, Loic Verlingue, Rama Balaraman, Leslie DeMars, Kate Josephs, Cong Xu, Oscar Reig Torras

Read the Full Article.

Patrizia Giannatempo

Andrea Necchi Antoine Italiano ASCO25 cancer Cancer research Cong Xu Ignacio Duran Kate Josephs Leslie DeMars Loic Verlingue Matthew Galsky Meredith McKean OncoDaily Oncology Oscar Reig Torras Patrizia Giannatempo Rama Balaraman Valentina Boni
Special Coverage
Opinion
Jul 9, 2025, 21:08
Paolo Tarantino Opens the 3rd Annual ADC Toxicity Summit
Insight
Jul 9, 2025, 21:02
Marianna Vitaloni: I'm Incredibly Grateful to the Patients Who Shared Their Stories With Us
Blog
Jul 9, 2025, 20:28
Jennifer Guida: I Had the Privilege to Lead Pioneering Work at the NCI Focused on Cancer Survivorship, Healthy Aging, and Resilience
Blog
Jul 9, 2025, 20:10
Every Person Living with NCDs Such as Cancer Has Access to the Treatment and Care They Need - UICC
Blog
Jul 9, 2025, 19:55
Erythropoietin Promotes an Immunosuppressive Tumor Microenvironment in Liver Cancer Models - NCI Division of Cancer Biology
Blog
Jul 9, 2025, 19:35
UF Health Cancer Center Welcomed Nearly 150 Middle and High School Science Teachers From Across the Southeast
Blog
Jul 9, 2025, 19:16
SIOP Provides Scholarships to Nurses Who Have Insufficient Resources to Participate and to Travel to Our Congress
Blog
Jul 9, 2025, 18:36
2nd Synergies Forum Marks Milestone for Pediatric and Young Adult Cancer Advocacy in Europe - ELLOK
Insight
Jul 9, 2025, 18:16
Akhil Kapoor: We Acknowledge and Appreciate the Trial’s Bold and Innovative Approach in Challenging Established Treatment Paradigms
Blog
Jul 9, 2025, 17:59
Afreen Shariff: Ready to Take Cancer Care to New Heights?
Blog
Jul 9, 2025, 17:48
Adrian Pogacian: New Developments in Scanxiety Live Webinar
Blog
Jul 9, 2025, 17:36
Wafaa M Rashed: Ethics, Equity and Policy - Through the Eyes of a Future Leader